MR perfusion measures coronary stenoses
Quantitative myocardial first-pass perfusion can distinguish coronary artery stenoses with a high degree of specificity and negative predictive value. The test offers an alternative to diagnostic catheterization to grade the severity of coronary artery disease, according to a presentation at the North American Society of Cardiac Imaging meeting.
Quantitative myocardial first-pass perfusion can distinguish coronary artery stenoses with a high degree of specificity and negative predictive value. The test offers an alternative to diagnostic catheterization to grade the severity of coronary artery disease, according to a presentation at the North American Society of Cardiac Imaging meeting.
Dr. Prasad M. Panse and colleagues at the University of Florida at Jacksonville studied 41 patients who underwent catheter angiography and MR first-pass perfusion. The sensitivity, specificity, PPV, and NPV for MR imaging to detect severe stenosis as determined visually from coronary angiograms were 67.6%, 90.1%, 56.5%, and 94.5%, respectively, for each sector. The low per-sector sensitivity was likely the result of microvascular disease, small-vessel disease in diabetic patients, subendocardial ischemia, or other cardiac risk factors. On a per-patient basis, sensitivity rose to 92%.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
